A Single-centre, Randomized, Double-blind (Sponsor Open), Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2983559, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Participants
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Jan 2018
At a glance
- Drugs GSK-2983559 (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline
- 08 Jan 2018 Planned End Date changed from 4 Mar 2019 to 22 Apr 2019.
- 08 Jan 2018 Planned primary completion date changed from 4 Mar 2019 to 22 Apr 2019.
- 04 Dec 2017 New trial record